Compare Charles River Laboratories Intl. Inc (CRL) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Nasdaq Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $228.01 (market cap $11.14B), while Nasdaq Inc trades at $90.85 (market cap $49.77B). The key difference: Nasdaq Inc is far larger — about 4.5× Charles River Laboratories Intl. Inc's market cap, and Nasdaq Inc pays a 1.27% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | NDAQ | |
|---|---|---|
Market Cap | $11.14B | $49.77B |
Sector | Health | Financials |
52-Week High | $233.60 | $100.98 |
52-Week Low | $145.57 | $76.85 |
Enterprise Value | $14.00B | $56.84B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Nasdaq (NDAQ) trades at $89.21, up 1.28% with a bullish technical signal and strong earnings momentum, beating estimates for three consecutive quarters. The company reported robust 2025 revenue of $8.26 billion and net income of $1.79 billion, with a net margin of 23.03%. Recent news highlights include SK Hynix's Nasdaq debut and positive analyst coverage, with 61% of analysts rating it a buy.
Outlook remains positive given earnings consistency and a $105.60 consensus price target, but risks include high valuation multiples and debt levels. Cash flow volatility from investing and financing activities warrants monitoring, though operational strength supports growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
